Skip to content
Medical Health Aged Care, Research Development

Rural health symposium to set the course for future research

National Rural Health Alliance 2 mins read

The 9th Rural and Remote Health Scientific Symposium held on 20 and 21 June 2023 anticipates over 200 delegates from the health sector to arrive in Canberra to help shape the future of rural and remote health research.

It has an exciting line-up of high-profile speakers and a program for delegates to learn, mentor, contribute and network.

The Hon Emma McBride MP, Assistant Minister for Rural & Regional Health and Assistant Minister for Mental Health & Suicide Prevention, will address delegates on the first day, followed by Adjunct Professor Ruth Stewart, National Rural Health Commissioner.

Delegates will also hear from James Blackwell, Research Fellow in Indigenous Diplomacy at the Australian National University, and member of the Uluru Dialogue at the University of New South Wales.

“A diverse range of themes will be covered in the sessions including paediatrics to aged care, chronic disease, workforce, cancer, avoiding hospital admission, prevention, mental health, telehealth, training, co-design, research through to disaster and climate impacts,” said the Alliance Chief Executive Susi Tegen.

“Delegates can also attend workshops and listen to a panel discussion on the importance of rural and remote health research and funding,” Ms Tegen added.

Other keynote and panel speakers include Dr Kim Houghton, Chief Economist at the Regional Australia Institute; physician and cardiologist Dr Arnagretta Hunter; Richard Juckes, Head of Population Health at the Australian Institute of Health and Welfare (AIHW); Professor Jennifer May AM, Director of the University of Newcastle Department of Rural Health and Betty Fyffe Chair of Rural Health; Frank Quinlan, Federation Executive Director of the Royal Flying Doctor Service of Australia; and Dr Masha Somi, Chief Executive Officer of the Health and Medical Research Office within the Australian Government Department of Health and Aged Care.

“The Symposium is less than two weeks away. We encourage those who haven’t already registered not to miss out on this opportunity to connect research, practice and communities.

“We thank our partners, Australian Rural Health Education Network (ARHEN), the Federation of Rural Australian Medical Educators (FRAME) and the Lowitja Institute for making this possible,” Ms Tegen added.

Click here to register.

Contact the Alliance on 02 6285 4660 or [email protected] with queries.

 

Ends. 


About us:

The National Rural Health Alliance (the Alliance) comprises 48 national organisations committed to improving the health and wellbeing of the 7 million people in rural and remote Australia. Our diverse membership includes representation from the Aboriginal and Torres Strait Islander health sector, health professional organisations, health service providers, health educators and students.


Contact details:

Susanne Tegen
(Chief Executive) 0429 100 464
Kathya de Silva
(Media & Communications Officer) 0470 487 608

Media

More from this category

  • Medical Health Aged Care
  • 08/12/2025
  • 17:10
Galderma Group AG

Galderma Welcomes Increased Equity Investment From L’Oréal

L’Oréal to acquire an additional 10% stake in Galderma recognizing its scientific leadership in dermatology and long-term growth potential Ad hoc announcement pursuant to…

  • Contains:
  • Medical Health Aged Care
  • 08/12/2025
  • 10:11
BeOne Medicines Ltd.

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies

Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLL Sonrotoclax in combination with BRUKINSA demonstrated rapid…

  • Contains:
  • Medical Health Aged Care
  • 08/12/2025
  • 09:40
Miltenyi Biomedicine

Miltenyi Biomedicine presents primary analysis of the pivotal DALY 2-EU trial for second-line relapsed/refractory large B-cell lymphoma at the 67th American Society of Hematology (ASH) Annual Meeting

DALY 2-EU results show zamtocabtagene autoleucel (zamto-cel) demonstrated clinically meaningful superiority over chemoimmunotherapy in patients with relapsed/refractory large B-cell lymphoma (r/r LBCL)1Zamto-cel was well-tolerated in the majority of patients. DALY 2-EU included a high-risk study population, characterized by older age and clinically high-risk disease featuresA 12-day manufacturing time resulted in a vein-to-vein time of 14-16 days, reducing the likelihood for bridging therapy.BERGISCH GLADBACH, Germany, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Miltenyi Biomedicine today announced results from the pivotal DALY 2-EU trial evaluating the efficacy and safety of zamtocabtagene autoleucel (zamto-cel) compared with standard chemoimmunotherapy (R-GemOx or Pola-BR) in patients with…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.